there has been low sensitivity for tumor-specific markers. We hypothesize that the low 34 sensitivity is due to the targeted assay methods. Therefore, we profiled the genome-wide CpG 
in this study has the potential to complement the standard of care for patients harboring glioma. 
INTRODUCTION

50
Gliomas are a heterogenous group of intracranial tumors that are constantly evolving, generally 51 recur, and frequently progress to more malignant subtypes. Recently, genomic and epigenomic 52 alterations have defined subtypes of glioma (e.g., IDH mutation, 1p19q chromosomal deletion,
53
and Glioma-CpG Island Methylator Phenotype [G-CIMP] ) with distinct prognostic outcomes [1] [2] [3] [4] [5] [6] .
54
Currently, this molecular diagnosis and classification, which guides clinical management, is 55 dependent on tissue profiling obtained by invasive surgical approaches (tissue biopsy or 56 excision). However, this surgery-centered approach does not allow serial tissue evaluation to 57 capture the dynamic molecular evolution of these tumors, may not be feasible in surgically 58 inaccessible tumors, requires the risk of an invasive procedure in an often comorbid population,
59
and may delay the diagnosis of this disease to later stages due to procedure risks and diagnostic 60 sensitivity. MRI is a relevant non-invasive approach to diagnose and follow patients with glioma; 61 however, limitations remain for differential diagnosis (e.g., lymphoma), detection of minimal or 62 remnant tumoral burden, and in distinguishing progression from pseudo-progression caused by 63 radiation-induced necrosis or treatments such as immunotherapy 7, 8 . In addition, serial 64 assessments may be costly and cumbersome procedures for patients. Therefore, the discovery of 65 a minimally or non-invasive approach that allow earlier identification of sensitive and specific 66 molecular biomarkers that reflect tumor burden and its dynamic evolution in real-time is
67
desirable. An approach that meets the above criteria is liquid biopsy (LB) of biofluids (e.g.,
68
blood, and cerebrospinal fluid [CSF] ) which detect materials shed by the tumors such as 69 circulating tumor cells and genomic specimens (e.g., circulating tumor DNA) 9, 10 .
70
In the past decade, investigation of the diagnostic, prognostic and predictive applications of LB 71 throughout a patient's disease course has been feasible in many tumors [11] [12] [13] [14] [15] [16] . For instance, in by eLB has the potential to improve the pre-and post-surgical quality of care for patients 118 harboring gliomas.
119
RESULTS
120
Glioma cell-free DNA methylome 121 In this study, we selected 22 matching pairs of primary glioma tissue and serum, stored at the and may be released more abundantly in more aggressive subtypes.
141
We performed an epigenome-wide profile of the glioma cfDNA using Infinium Human
142
Methylation 850K (HM850K). Filtering and pre-processing steps were taken to align these data 143 with that of serum methylome data from colorectal cancer (N=2) 44 and, consequently, be detectable via analysis of the serum methylome.
177
Glioma eLB derived from cell-free DNA in serum can identify patients with glioma
178
We performed an epigenome-wide differential analysis to identify specific, serum-based,
179
epigenetic markers associated with glioma compared to non-glioma serum methylome, which we 180 named Glioma-eLB (N=1075 differential CpG sites overlapping autosomal chromosomes,
181
Wilcoxon-rank sum test p-value < 0.001, Extended Data Fig. S2A relative to non-tumor controls using 11 randomly selected cases from the initial cohort (N=22).
213
Next, we trained a ML model (RandomForest) using the Glioma-eLB on the training set. This
214
provided us with a Glioma-eLB Index (GI), which estimates the probability that a sample is 215 likely a glioma (high GI or close to 1) or non-glioma (low GI or close to 0 (summarized in Fig. 4A ). In addition, epigenetic profiling has the advantage of providing 290 information about the tumor microenvironment, which usually lacks somatic mutations 33 .
291
Deconvolution analysis allowed us to estimate that the Glioma-eLB were associated with tissue and serum and considered them tissue-specific.
437
Random Forest
438
We used a random forest ML model with the aim to classify available cfDNA methylation
439
(serum or plasma and tissue) derived from tumor patients, patients with metastasis of unknown 440 primary, non-tumor conditions (sepsis, pancreatic islet transplantation recipient) and non-441 tumor/non-diseased cell-free DNA and non-tumor brain and glioma tissue from TCGA.
442
To validate the performance of our ML model, for this specific approach, we randomly selected 443 11 glioma serum samples and used this set to compare to the 3 non-tumor serum samples and 444 derived a new glioma-tissue specific signature (top 1000 most significant probes). We then used 445 this set of 11 glioma serum samples and 3 non-tumor serum samples to train the random forest
446
ML model. We tested the remaining 11 glioma serum samples using our model, ensuring to 447 bootstrap 1000 times to reduce training/test biases. We named the output probability score of the 448 random forest model Glioma-eLB index (GI). 
449
Gene Expression and integrative analysis
Beta-values
MGMT promoter
Non tumor A) Epigenome-wide mean DNA methylation across our patient cohort's serum cfDNA methylation (y-axis: three nontumor samples and x-axis: 22 glioma-patient-derived serum samples). Non-significant CpG methylation probes (pvalue > 5%) are condensed into a density heatmap by calculating the 2D kernel density estimation to the power of 0.1. Identified cfDNA methylation signatures associated with glioma patients (N=1,075) are selected by different pvalues (black, p-value < 0.05; blue, and red, p-value < 0.001). Glioma-eLB signatures (p-value < 0.001) are further divided into CpGs that are measurable (Glioma tissue specific, red) or not measurable in the matching glioma tissue (Non-tissue specific, blue). B) Principal Component Analysis using the Glioma-eLB signatures as input. Serum methylome from glioma, pituitary tumors, CRC and non-tumor samples are represented. C) Glioma-specific tissuematching eLB (N=384) was used to subset the published primary tumor tissue DNA methylation and using t-SNE (tdistributed stochastic neighbour embedding) dimensionality reduction to visualize the similarities of each sample. As expected, each primary tumor type (circles) clusters with its known cell-of-origin. Serum cfDNA methylation of our patients cohort (triangles) clusters with the primary glioma tissue DNA methylation profiles. D) Dendrogram of non-tumor cell types in comparison to Glioma-eLB (N=384). Based on the mean DNA methylation across each cell type, this dendrogram shows that glioma serum cfDNA clusters with relevant immune cell-types along with glialderived cells and bulk brain (non-tumor) samples. E) Machine learning (ML) application (Random Forest) using our defined Glioma tissue-specific eLB to classify tumors and available cfDNA methylation (serum or plasma) derived from tumor patients, patients with metastasis of unknown primary, non-tumor conditions (e.g., sepsis, pancreatic islet transplantation recipient) and non-tumor/non-diseased cell-free DNA. Y-axis represents the ML similarity index based on Glioma-eLB signatures averaged across 1000 iterations. Zero indicates low probability of a glioma, while 1 indicates high probability of a sample being a glioma. Dash line indicates cutoff to determine glioma classification. F) Receiver operating characteristic curve derived from the average across 1000 cross validation. Specificity and sensitivity calculated at 0.05 increments (N=21) from 0 to 1 Glioma-eLB signature index. A) Mean DNA methylation of 750,000 CpG across 15 IDH mut-patient derived serum (x-axis) vs 7 IDH wtpatient derived serum (y-axis). Non-significant CpG methylation probes are condensed into a density heatmap by calculating the 2D kernel density estimation to the power of 0.1. Proposed prognostic glioma-specific eLB (N=1,075) selected by p-values are represented by colored dots (black, p-value < 0.05; blue, red and yellow, p-value < 0.01). Similarities across selected tumor tissue and serum, using IDH mut-tissue specific eLB levels (red circles) and IDH wt-tissue specific eLB levels (yellow circles). B-C) Similarities across Pan-Glioma tissue (N=259 IDH mut and 160 IDH wt) and IDH glioma cfDNA methylation (N=15 IDH mut, 7 IDH wt), using IDH mut-tissue specific eLB signatures B) and IDH wt-tissue specific eLB signatures C) as input in a t-SNE analysis to visualize the similarities by sample. 
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Time ( A) Steps used to generate the eLB and the application of a machine learning (ML) model to predict glioma and glioma subtypes. B) At specific intervals, currently determined by magnetic resonance imaging (MRI) visits, patients' whole-blood is collected and serum/plasma is immediately processed. cfDNA is isolated and profiled using DNA methylation microarray (profile >700,000 CpGs across the entire human genome) and entered into a ML algorithm to generate a index (Glioma-index). C) According to the predetermined index threshold (0.6, sensitivity: 98%; specificity: 99%), the new sample is classified as glioma or non-glioma and according to IDH status (mutant or wildtype). The discovered glioma specific eLB (N=1,075) can be used to complement current clinical diagnostic and monitoring events. Prognostic IDH-eLB could be used at time of diagnosis and for monitoring during active treatment through survivorship care. Complementing the MRI findings, eLB could improve detection, reduce false-positive and increase tumor identification (glioma vs necrosis vs non glioma conditions), assess treatment outcome and help tailor treatment options for patients with glioma. eLB could also foster early detection of glioma progression to improve treatment outcomes. Future clinical trials are needed to evaluate the robustness of our eLB signatures for clinical application. 
